CAMBRIDGE, England, June 14, 2010 Executives from SenexisLimited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) underwhich O2h will provide Senexis with chemistry services to support a patentfiling on a novel chemical series that have shown potential in pre-clinicalmodels, as disease modifying treatments for Alzheimer's Disease.
Dr. Mark Treherne, CEO of Senexis said that he appreciated O2h'scontinual support over the last 4 years in being a reliable chemistrypartner, providing flexible multi-FTE chemistry support to the company.
Dr David Scopes, CSO at Senexis said "We have had a long collaborationwith O2h and are happy that it is supporting us to further our programs intothe important stage of patent applications. Senexis is again leveraging O2h'sexpertise on the synthetic chemistry methodology underpinning our leadcompounds."
Sunil Shah, CEO, O2h "We have an incredibly good relationship and I wasvery happy learn about the positive Senexis data from their pre-clinicalstudies which allowed the Wellcome Trust to continue supporting thisprogramme."
About Oxygen Healthcare Ltd
O2h is a 5 year old discovery services company co-located in Cambridge,UK and Ahmedabad, India. The Indian operations provide a high level ofchemistry expertise while UK office provides project management support.Current clients of O2h include several top 20 pharmaceutical andbiotechnology companies in the US, Europe and Japan. O2h adheres to thehighest standards of performance with a particular emphasis on rapidinteractive communications and delivery speed. Services provided by O2hinclude FTE-based synthetic chemistry, medicinal chemistry, computationalchemistry, full services lab-units and ADME. Further information on O2h canbe found at http://www.o2h.com.
About Senexis Limited
Senexis is a drug discovery and development company, dedicated to thediscovery of effective treatments and diagnostics for major ageing-relateddiseases, such as Alzheimer's dementia. It is now widely believed that themisfolding and aggregation of amyloid-like proteins underlies the pathologiesof Alzheimer's disease and Senexis has discovered potent and selectivecompounds that protect cells and tissues from the toxic forms of amyloid.Senexis is now actively seeking development partners and further informationon Senexis can be found at http://www.senexis.com.Contact information: Ekta Ahuja PhD firstname.lastname@example.org OXYGEN HEALTHCARE LTD 23 Cambridge Science Park CB4 0EY Contact: SENEXIS LIMITED Babraham Research Campus Babraham, Cambridge, UK CB22 3AT
SOURCE Oxygen Healthcare Ltd (O2h)